P1, N=96, Enrolling by invitation, Tianjin Chasesun Pharmaceutical Co., LTD | N=186 --> 96 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

6 months ago

Enrollment change • Trial completion date • Trial primary completion date • Metastases

IMMH-010

over1year

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)

P1, N=186, Enrolling by invitation, Tianjin Chasesun Pharmaceutical Co., LTD | Unknown status --> Enrolling by invitation | Phase classification: P1/2 --> P1 | N=96 --> 186 | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Dec 2023

over 1 year ago

Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases

PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)

PD-L1 expression • MSI-H/dMMR

IMMH-010

3years

Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug. (PubMed, Pharmaceutics)

We also compared the pharmacokinetic profiles of IMMH-010 in rodents and primates. After oral administration of IMMH-010, the general exposure of active metabolite YPD-29B was slightly lower in primates than in rodents, suggesting that data should be extrapolated cautiously from rodents to humans.

3 years ago

Journal

PD-L1 (Programmed death ligand 1) • CES1 (Carboxylesterase 1)

IMMH-010

4years

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)

P1/2, N=96, Not yet recruiting, Tianjin Chasesun Pharmaceutical Co., LTD

4 years ago

Clinical • New P1/2 trial

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PD-L1 overexpression

IMMH-010